Positive results with lenvatinib for the treatment of advanced medullary thyroid cancer in a phase II trial

被引：0
|
作者：
机构：
来源：
Nature Reviews Endocrinology | 2015年 / 11卷 / 11期
关键词：
D O I：
10.1038/nrendo.2015.157
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：632 / 632
相关论文
共 50 条
  • [21] Beneficial Effects of the mTOR Inhibitor Everolimus in Patients with Advanced Medullary Thyroid Carcinoma: Subgroup Results of a Phase II Trial
    Schneider, T. C.
    de Wit, D.
    Links, T. P.
    van Erp, N. P.
    van der Hoeven, J. J. M.
    Gelderblom, H.
    van Wezel, T.
    van Eijk, R.
    Morreau, H.
    Guchelaar, H. J.
    Kapiteijn, E.
    INTERNATIONAL JOURNAL OF ENDOCRINOLOGY, 2015, 2015
  • [22] Efficacy of Sunitinib in Advanced Medullary Thyroid Carcinoma: Intermediate Results of Phase II THYSU
    Ravaud, Alain
    de la Fouchardiere, Christelle
    Asselineau, Julien
    Delord, Jean-Pierre
    Do Cao, Christine
    Niccoli, Patricia
    Rodien, Patrice
    Klein, Marc
    Catargi, Bogdan
    ONCOLOGIST, 2010, 15 (02): : 212 - 213
  • [23] Cabozantinib for the Treatment of Advanced Medullary Thyroid Cancer
    Madhavi Nagilla
    Rebecca L. Brown
    Ezra E. W. Cohen
    Advances in Therapy, 2012, 29 : 925 - 934
  • [24] A Phase II Trial of Bexarotene for Advanced Differentiated Thyroid Cancer
    Klopper, Joshua
    Kane, Madeleine
    Jimeno, Antonio
    Sams, Sharon
    French, Jena
    Pike, Laura
    Tompkins, Kenneth
    Haugen, Bryan
    THYROID, 2015, 25 (05) : 563 - 564
  • [25] Phase 3 Trial of Selpercatinib in Advanced RET-Mutant Medullary Thyroid Cancer
    Hadoux, J.
    Elisei, R.
    Brose, M. S.
    Hoff, A. O.
    Robinson, B. G.
    Gao, M.
    Jarzab, B.
    Isaev, P.
    Kopeckova, K.
    Wadsley, J.
    Fuehrer, D.
    Keam, B.
    Bardet, S.
    Sherman, E. J.
    Tahara, M.
    Hu, M. I.
    Singh, R.
    Lin, Y.
    Soldatenkova, V
    Wright, J.
    Lin, B.
    Maeda, P.
    Capdevila, J.
    Wirth, L. J.
    NEW ENGLAND JOURNAL OF MEDICINE, 2023, 389 (20): : 1851 - 1861
  • [26] A phase II trial of doxorubicin and interferon alpha 2b in advanced, non-medullary thyroid cancer
    Argiris, Athanassios
    Agarwala, Sanjiv S.
    Karamouzis, Michalis V.
    Burmeister, Lynn A.
    Carty, Sally E.
    INVESTIGATIONAL NEW DRUGS, 2008, 26 (02) : 183 - 188
  • [27] A phase II trial of doxorubicin and interferon alpha 2b in advanced, non-medullary thyroid cancer
    Athanassios Argiris
    Sanjiv S. Agarwala
    Michalis V. Karamouzis
    Lynn A. Burmeister
    Sally E. Carty
    Investigational New Drugs, 2008, 26 : 183 - 188
  • [28] Surufatinib in Chinese Patients with Locally Advanced or Metastatic Differentiated Thyroid Cancer and Medullary Thyroid Cancer: A Multicenter, Open-Label, Phase II Trial
    Chen, Jiaying
    Ji, Qinghai
    Bai, Chunmei
    Zheng, Xiangqian
    Zhang, Yuan
    Shi, Feng
    Li, Xiaojiang
    Tang, Pingzhang
    Xu, Zhengang
    Huang, Rui
    Huang, Tao
    Pan, Yueyin
    Fan, Songhua
    Zhou, Jinghong
    Su, Weiguo
    THYROID, 2020, 30 (09) : 1245 - 1253
  • [29] Efficacy of Sunitinib in Advanced Medullary Thyroid Carcinoma: Intermediate Results of Phase II THYSU Reply
    Bugalho, Maria Joao
    ONCOLOGIST, 2010, 15 (02): : 214 - 214
  • [30] Everolimus in Patients With Advanced Follicular-Derived Thyroid Cancer: Results of a Phase II Clinical Trial
    Schneider, Tatiana C.
    de Wit, Djoeke
    Links, Thera P.
    van Erp, Nielka P.
    van der Hoeven, Jakobus J. M.
    Gelderblom, Hans
    Roozen, Inge C. F. M.
    Bos, Manon
    Corver, Wim E.
    van Wezel, Tom
    Smit, Jan W. A.
    Morreau, Hans
    Guchelaar, Henk-Jan
    Kapiteijn, Ellen
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2017, 102 (02): : 698 - 707
12345